Bicycle Therapeutics (BCYC) Expected to Post Quarterly Earnings on Thursday

Key Points

• Bicycle Therapeutics is expected to report Q3 2026 results on October 29 before the market opens, with analysts forecasting a loss of $0.399 per share and revenue of $12.22 million.
• The company’s previous quarter fell short of expectations, reporting a $0.72-per-share loss and $0.63 million in revenue versus estimates of a $0.58 loss and $4.22 million in revenue.
• BCYC shares opened at $3.57, near their 52-week low, while analyst sentiment remains mixed: the consensus rating is “Hold” with a $13.86 price target, despite recent sell-rating downgrades.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Bicycle Therapeutics to announce earnings of ($0.3990) per share and revenue of $12.22 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 7:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The company had revenue of $0.63 million during the quarter, compared to analyst estimates of $4.22 million. On average, analysts expect Bicycle Therapeutics to post ($2.26) EPS for the current fiscal year and ($2.27) EPS for the next fiscal year.

Bicycle Therapeutics Stock Down 0.8%

Shares of NASDAQ BCYC opened at $3.57 on Thursday. The firm has a market cap of $249.86 million, a price-to-earnings ratio of -1.31 and a beta of 1.68. Bicycle Therapeutics has a 52-week low of $3.33 and a 52-week high of $9.08. The business's 50 day moving average is $3.89 and its two-hundred day moving average is $4.23.

Analysts Set New Price Targets

BCYC has been the subject of several research analyst reports. Zacks Research lowered Bicycle Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Wall Street Zen upgraded Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 15th. Finally, Needham & Company LLC decreased their target price on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bicycle Therapeutics presently has an average rating of "Hold" and a consensus target price of $13.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc NASDAQ: BCYC is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.